Skip Navigation

JNCI Monographs 2003 2003(31):80-88;
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Iftner, T.
Right arrow Articles by Villa, L. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Iftner, T.
Right arrow Articles by Villa, L. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute Monographs, No. 31, 80-88, 2003
© 2003 Oxford University Press

ARTICLE

Chapter 12: Human Papillomavirus Technologies

Thomas Iftner, Luisa Lina Villa

Affiliations of authors: T. Iftner, Medical Virology, Section Experimental Virology, University Hospital of Tuebingen, Tuebingen, Germany; L.L. Villa, Virology, Ludwig Institute for Cancer Research, Sao Paulo, Brazil.

Correspondence to: Thomas Iftner, Ph.D., Institut fuer Medizinische Virologie, Sektion Experimentelle Virologie, Universitatetsklinikum Tuebingen, Elfriede-Aulhorn Str. 6, 72076 Tuebingen (e-mail: tsiftner{at}med.uni-tuebingen.de).

Currently, human papillomavirus (HPV) DNA tests validated in large trials and epidemiological studies are the hybrid capture second-generation (HC2) HPV DNA assay and a variety of polymerase chain reaction (PCR) protocols employing degenerate or consensus primers. This article describes the currently available technology for HPV detection and discusses novel technologies and their potential for large-scale screening. Ideally, an HPV test should allow detection of multiple HPV types, identify individual types, and provide quantitative information about the viral load of each individual type found. Moreover, it should be easy to perform, be highly reproducible, with a high specificity and sensitivity, and amenable for high throughput analysis and automation. Because we do not yet fully understand the true value of viral load and the biological relevance of the different HPV types, any HPV test should be able to detect the clinically relevant high-risk types with a sufficient sensitivity of at least 10 000 genome copies per sample. To validate the different current and future test systems and to compare inter-laboratory performance we urgently need reference samples, validated reagents, and standardized protocols.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Microbiol.Home page
M. Safaeian, R. Herrero, A. Hildesheim, W. Quint, E. Freer, L.-J. Van Doorn, C. Porras, S. Silva, P. Gonzalez, M. C. Bratti, et al.
Comparison of the SPF10-LiPA System to the Hybrid Capture 2 Assay for Detection of Carcinogenic Human Papillomavirus Genotypes among 5,683 Young Women in Guanacaste, Costa Rica
J. Clin. Microbiol., May 1, 2007; 45(5): 1447 - 1454.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Kjaer, E. Hogdall, K. Frederiksen, C. Munk, A. van den Brule, E. Svare, C. Meijer, A. Lorincz, and T. Iftner
The Absolute Risk of Cervical Abnormalities in High-risk Human Papillomavirus-Positive, Cytologically Normal Women Over a 10-Year Period
Cancer Res., November 1, 2006; 66(21): 10630 - 10636.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.